Tackling drug resistance and other causes of treatment failure in leishmaniasis
GJ Wijnant, F Dumetz, L Dirkx, D Bulté… - Frontiers in Tropical …, 2022 - frontiersin.org
Leishmaniasis is a tropical infectious disease caused by the protozoan Leishmania parasite.
The disease is transmitted by female sand flies and, depending on the infecting parasite …
The disease is transmitted by female sand flies and, depending on the infecting parasite …
Exploiting knowledge on Leishmania drug resistance to support the quest for new drugs
A Hefnawy, M Berg, JC Dujardin, G De Muylder - Trends in parasitology, 2017 - cell.com
New drugs are needed to control leishmaniasis and efforts are currently on-going to counter
the neglect of this disease. We discuss here the utility and the impact of associating drug …
the neglect of this disease. We discuss here the utility and the impact of associating drug …
Evolutionary genomics of epidemic visceral leishmaniasis in the Indian subcontinent
Leishmania donovani causes visceral leishmaniasis (VL), the second most deadly vector-
borne parasitic disease. A recent epidemic in the Indian subcontinent (ISC) caused up to …
borne parasitic disease. A recent epidemic in the Indian subcontinent (ISC) caused up to …
Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to …
Background Miltefosine (MIL) is an oral antileishmanial drug used for treatment of visceral
leishmaniasis (VL) in the Indian subcontinent. Recent reports indicate a significant decline in …
leishmaniasis (VL) in the Indian subcontinent. Recent reports indicate a significant decline in …
[HTML][HTML] Genomic and transcriptomic alterations in Leishmania donovani lines experimentally resistant to antileishmanial drugs
A Rastrojo, R García-Hernández, P Vargas… - International Journal for …, 2018 - Elsevier
Leishmaniasis is a serious medical issue in many countries around the World, but it remains
largely neglected in terms of research investment for developing new control and treatment …
largely neglected in terms of research investment for developing new control and treatment …
In vitro selection of miltefosine resistance in promastigotes of Leishmania donovani from Nepal: genomic and metabolomic characterization
CD Shaw, J Lonchamp, T Downing… - Molecular …, 2016 - Wiley Online Library
In this study, we followed the genomic, lipidomic and metabolomic changes associated with
the selection of miltefosine (MIL) resistance in two clinically derived Leishmania donovani …
the selection of miltefosine (MIL) resistance in two clinically derived Leishmania donovani …
Molecular Mechanisms of Drug Resistance in Natural Leishmania Populations Vary with Genetic Background
S Decuypere, M Vanaerschot, K Brunker… - PLoS neglected …, 2012 - journals.plos.org
The evolution of drug-resistance in pathogens is a major global health threat. Elucidating the
molecular basis of pathogen drug-resistance has been the focus of many studies but rarely …
molecular basis of pathogen drug-resistance has been the focus of many studies but rarely …
Antimony-resistant but not antimony-sensitive Leishmania donovani up-regulates host IL-10 to overexpress multidrug-resistant protein 1
B Mukherjee, R Mukhopadhyay… - Proceedings of the …, 2013 - National Acad Sciences
The molecular mechanism of antimony-resistant Leishmania donovani (SbRLD)–driven up-
regulation of IL-10 and multidrug-resistant protein 1 (MDR1) in infected macrophages (Mϕs) …
regulation of IL-10 and multidrug-resistant protein 1 (MDR1) in infected macrophages (Mϕs) …
Development and evaluation of a cedrol-loaded nanostructured lipid carrier system for in vitro and in vivo susceptibilities of wild and drug resistant Leishmania …
N Kar, S Chakraborty, AK De, S Ghosh… - European Journal of …, 2017 - Elsevier
Leishmaniasis is an epidemic in various countries, and the parasite Leishmania donovani is
developing resistance against available drugs. In the present study the antileishmanial …
developing resistance against available drugs. In the present study the antileishmanial …
Febrifugine analogues as Leishmania donovani trypanothione reductase inhibitors: binding energy analysis assisted by molecular docking, ADMET and molecular …
Visceral leishmaniasis affects people from 70 countries worldwide, mostly from Indian,
African and south American continent. The increasing resistance to antimonial, miltefosine …
African and south American continent. The increasing resistance to antimonial, miltefosine …